Summary
Edwards Lifesciences Corporation reported strong revenue growth in the third quarter and first nine months of 2016, driven significantly by its Transcatheter Heart Valve Therapy (THVT) segment, particularly the SAPIEN 3 valve. Net sales increased by 20.1% year-over-year for the quarter and 20.5% for the year-to-date period. This top-line growth translated into a substantial increase in net income, up 19.7% for the quarter and 16.0% for the nine months, reflecting improved operational performance and strategic product launches. Despite robust sales, the company's gross profit margin experienced pressure, primarily due to unfavorable foreign currency exchange rate fluctuations. However, management highlighted an improving product mix driven by THVT as a partial offset. Significant investments in research and development (R&D) continue, with 15.0% of net sales dedicated to R&D in the first nine months of 2016, underscoring the company's commitment to innovation. Investors should note the ongoing intellectual property litigation with Boston Scientific, which, while not expected to materially impact the company's overall financial position, carries inherent uncertainties.
Financial Highlights
49 data points| Revenue | $739.40M |
| Cost of Revenue | $201.40M |
| Gross Profit | $538.00M |
| R&D Expenses | $113.00M |
| SG&A Expenses | $229.60M |
| Interest Expense | $2.10M |
| Net Income | $141.40M |
| EPS (Basic) | $0.22 |
| EPS (Diluted) | $0.22 |
| Shares Outstanding (Basic) | 639.60M |
| Shares Outstanding (Diluted) | 654.30M |
Key Highlights
- 1Net sales increased by 20.1% to $739.4 million for the third quarter and 20.5% to $2,196.0 million for the nine months ended September 30, 2016.
- 2Transcatheter Heart Valve Therapy (THVT) sales surged by 38.5% in the quarter and 41.4% year-to-date, largely due to the SAPIEN 3 valve launch and expansion.
- 3Net income grew by 19.7% to $141.4 million for the quarter and 16.0% to $411.0 million for the nine months, indicating strong profitability.
- 4Gross profit margin was negatively impacted by foreign currency exchange rate fluctuations, though partially offset by an improved product mix driven by THVT.
- 5Research and Development (R&D) expenses increased, reflecting continued investment in product development, with R&D representing 15.0% of net sales for the nine-month period.
- 6The company repurchased $380.9 million in treasury stock during the nine months ended September 30, 2016, as part of its share repurchase program.
- 7Significant ongoing legal proceedings related to intellectual property litigation with Boston Scientific are noted, with trials scheduled in 2017 and 2018.